Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00504972 | Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies | PHASE1 | COMPLETED | 23 | — | — | Jun 1, 2007 | Oct 7, 2015 | May 29, 2018 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Study Treatment | EXPERIMENTAL | This study is a single arm study |
| Name | Type | Description |
|---|---|---|
| hLL1 | DRUG | hLL1 administered intravenously once daily Monday through Friday for 2 consecutive weeks (10 total doses) at one of 4 planned dose levels: 1.5, 4, 6 or 8 mg/kg. |
Inclusion Criteria: * Histologically confirmed diagnosis of recurrent B cell non-Hodgkin's lymphoma or diagnosis of recurrent chronic lymphocytic leukemia * Patient has received at least one prior treatment with standard chemotherapy and at least one prior treatment with rituximab (negative HAHA te...